Mazdutide vs Retatrutide: Dual vs Triple Glucagon Map

People type mazdutide vs retatrutide like they found two pens in the same drawer.

They found two different keys for overlapping locks.

Mazdutide is a dual agonist. Dual means it is built to turn on two receptors, not one. Those two are the GLP-1 receptor and the glucagon receptor. Retatrutide is a triple agonist. Triple means three receptors: GIP, GLP-1, and glucagon. Same glucagon neighborhood. Extra GIP arm on one of them. Different companies running different files. Different approval status depending on the country you are standing in.

This page is the mazdutide vs retatrutide research map. It sits next to the live retatrutide page, the tirzepatide vs semaglutide dual-versus-single map, and the wider peptides for weight loss hub. Foundation still matters. Creatine benefits is grocery-aisle work, not a gut-hormone drug. Start with Start Here if peptides are not day one.

This is education. It is not medical advice. It is not a reason to skip a clinician. It is not a buy-this-to-lose-weight pitch. A research-catalog cake is not a branded obesity pen.

What is mazdutide vs retatrutide, actually?

A peptide is a short chain of amino acids. Insulin is a peptide. Semaglutide is a peptide. Tirzepatide is a peptide. Mazdutide is a peptide. Retatrutide is a peptide. Naming the format does not name the job.

Mazdutide also shows up in papers as IBI362 or LY3305677. It is a once-weekly injectable built as an analogue of oxyntomodulin. Oxyntomodulin is a natural gut hormone that already talks to both GLP-1 and glucagon receptors. Innovent Biologics developed it in China under a license from Eli Lilly. Lilly still runs a global file.

Retatrutide also shows up as LY3437943. Lilly designed it as a three-receptor drug candidate. GIP. GLP-1. Glucagon. The live map for that molecule is already on retatrutide.

So what is the actual comparison? Two engineered gut-hormone drugs. Both include the glucagon receptor. Only retatrutide adds GIP. That extra arm is the whole extra claim surface. Not “the same shot in a different color.”

The wow analogy: two locks versus three

Think of a house with three doors.

Door one is GLP-1. Appetite. Stomach emptying. Blood-sugar-linked insulin stories. Semaglutide was built to open this door. You know the brands as Ozempic and Wegovy.

Door two is GIP. A second gut-hormone receptor. Tirzepatide opens door one and door two. Brands: Mounjaro and Zepbound. That dual map already lives on tirzepatide vs semaglutide.

Door three is the glucagon receptor. Liver energy-use talks. Hepatic fat handling talks. Not a free “burn fat” caption. Mazdutide opens door one and door three. It leaves door two shut. Retatrutide tries all three.

More keys is not the same as “already approved at your US pharmacy.” More keys is also not a reason to stack two glucagon agonists because a forum said it would be sophisticated. Two glucagon agonists in one person is not a flex. It is a mess.

Receptor map in plain English

You do not need a hormone fellowship. You need four jobs and one warning.

• GLP-1 in one sentence: a gut hormone path tied to appetite, stomach emptying, and blood-sugar-linked insulin stories.
• GIP in one sentence: a second gut-hormone receptor. Tirzepatide adds it beside GLP-1. Mazdutide does not.
• Glucagon receptor in one sentence: the extra lock both of these molecules share. Discovery papers discuss energy-use and liver talks. It is not a vibe.
• Why a dual with glucagon exists: if you block glucagon you can mess with lipids and liver fat the wrong way. The bet here is the opposite — turn glucagon on, and let GLP-1 cover the blood-sugar side so the glucose rise does not run the show.

How sure are we about that last sentence? Medium-high on the mechanism story. Coskun and colleagues described the triple-agonist version of this idea in Cell Metabolism in 2022. Mazdutide is the two-lock cousin, not the three-lock cousin. Mechanism talk is not a shopping list.

Lane	What it actually is	What the evidence talk is	What it is not
Semaglutide	GLP-1 receptor agonist. Brands: Ozempic, Wegovy	Large randomized programs. Context on tirzepatide vs semaglutide	Not mazdutide. Not retatrutide. Not a research-catalog fragment
Tirzepatide	Dual GIP + GLP-1. Brands: Mounjaro, Zepbound	SURMOUNT programs. Head-to-head with semaglutide in SURMOUNT-5	Not a glucagon dual. Not a triple. Not a freeze-dried “upgrade”
Mazdutide / IBI362 / LY3305677	Dual GLP-1 + glucagon. Oxyntomodulin analogue. Once weekly in trials	China Phase 3 obesity file in NEJM. China T2D Phase 3 in Nature. US Phase 2 in 2026. Innovent announced China NMPA approval for chronic weight management in June 2025	Not an FDA retail pen in the US. Not retatrutide. Not tirzepatide
Retatrutide / LY3437943	Triple agonist at GIP, GLP-1, and glucagon. Still in development	Phase 2 obesity in NEJM 2023. Phase 2 type 2 diabetes in The Lancet 2023. Later papers and a liver-fat substudy	Not an FDA retail brand next to Zepbound. Not mazdutide with a third sticker

You can be interested in all four. You cannot mash them into one Reddit protocol and call the extra receptor a clinic result you bought with a coupon code.

Stop-you stat: GLORY-1 is a real Phase 3 file

Why this matters: most “next Ozempic” captions are Phase 2 screenshots. Mazdutide already has a published Phase 3 obesity trial in a major journal.

Ji and colleagues published GLORY-1 in the New England Journal of Medicine in 2025. Phase 3. Double-blind. Placebo-controlled. China. 610 adults. Mean body weight 87.2 kg. Mean BMI 31.1. People got 4 mg mazdutide, 6 mg mazdutide, or placebo once a week for 48 weeks.

Stop-you stat: at week 32, mean weight change was −10.09% on 4 mg, −12.55% on 6 mg, and +0.45% on placebo. At week 48 those means were −11.00%, −14.01%, and +0.30%. About half the 6 mg group lost at least 15% by week 48. Stomach side effects were the usual gut-hormone story, mostly mild to moderate. Drop-outs from adverse events were low.

How sure should you be? High confidence that this happened in that Chinese adult population under that protocol. Lower confidence that you can paste the percentage onto a US body, a different diet, or a research-catalog vial. Phase 3 in one country is not an FDA label in another. It is also not retatrutide.

Evidence limits, stated plainly:

• GLORY-1 and GLORY-2 are real Phase 3 obesity files in Chinese adults
• China T2D Phase 3 papers in Nature are real
• A US Phase 2 of mazdutide is real
• Retatrutide Phase 2 obesity, diabetes, and a small liver-fat substudy are real
• There is no completed head-to-head of mazdutide versus retatrutide in PubMed on this page
• A China NMPA announcement is not an FDA retail pen
• A research-catalog vial is not the trial product

GLORY-2 pushed a 9 mg dose in Chinese adults with BMI at least 30. Gao and colleagues published it in JAMA in 2026. At week 60, mean weight change was −16.65% with 9 mg versus −1.50% with placebo. Vomiting, nausea, and diarrhea were common. That is a higher-dose China obesity file. Still not a US retail sticker.

Retatrutide’s file is real. It is a different file

Jastreboff and colleagues published a Phase 2 obesity trial of retatrutide in the New England Journal of Medicine in 2023. 338 adults. Once weekly for 48 weeks. At 48 weeks the 12 mg group showed a least-squares mean weight change of −24.2% versus −2.1% on placebo.

That number is why group chats learned the word triple.

Foolish read: it is a Phase 2 signal, not a finished US label. Different people than GLORY-1. Different baseline. Different length. Different dose family. Coskun’s 2022 Cell Metabolism paper is the discovery file. A 2023 Lancet Phase 2 tested retatrutide in type 2 diabetes. A 2026 Lancet paper extends the type 2 diabetes control talk. Reviews are maps. They are not marching orders.

I will not stack −24.2% next to −12.55%, pound the table, and call it science. That is two photos from two vacations. If someone sells you a winner from a cross-trial collage, ask for the head-to-head. It does not exist on this page because it does not exist in PubMed as a completed dual-versus-triple trial I can cite.

The liver question people actually type

Searchers do not only want scale weight. They want the glucagon receptor because it sits on hepatocytes. Hepatocytes are liver cells. That is a real hepatic conversation, not a podcast mood.

Sanyal and colleagues ran a Phase 2a liver-fat substudy of retatrutide in Nature Medicine in 2024. Ninety-eight people from the obesity trial who already had metabolic dysfunction-associated steatotic liver disease and at least 10% liver fat. At 24 weeks, mean relative liver-fat change was −82.4% with 12 mg versus +0.3% with placebo. Some people in the higher-dose groups reached a “normal” liver-fat band under 5% on imaging.

How sure are we? The number is huge. The sample is small. It is a substudy, not a histology-proven MASH label. Relative change is not the same as “cured fatty liver.” Feeling better or eating less is not a liver readout. Wait for the scan with a clinician.

Mazdutide papers talk cardiometabolic measures and hepatic fat handling as part of the glucagon bet. GLORY-1 reported beneficial effects on prespecified cardiometabolic measures. That is not the same as a US liver-disease approval. I will not invent a liver-fat percentage I cannot pin to a primary paper.

Foundation still comes first. Sleep, protein, training, and creatine are not optional because a dual agonist has a glucagon arm. The creatine benefits page is that grocery-aisle map. This page will never say “skip creatine, buy a glucagon dual.”

Type 2 diabetes files, without turning this into a clinic

Mazdutide has China-focused type 2 diabetes Phase 3 work in Nature in 2026. One trial compared mazdutide with placebo in people whose diabetes was not controlled by diet and exercise alone. Another compared mazdutide with dulaglutide, a GLP-1 drug already in use. Both doses of mazdutide beat dulaglutide 1.5 mg on HbA1c and on weight in that 28-week file. HbA1c is the longer-look blood-sugar marker clinicians use.

How sure? Those are Phase 3 papers in a top journal. They are still China-population files. They are still not a reason to DIY a diabetes protocol from a blog.

Lilly also published a US Phase 2 of mazdutide in The Lancet Diabetes & Endocrinology in 2026. Adults with obesity or overweight, no type 2 diabetes. Doses up to 16 mg. At 32 weeks, least-squares mean weight change ran from about −7.3% on a low 3–6 mg path to −18.1% on 16 mg, versus −0.9% on placebo. Higher doses meant more gut side effects and more people stopping the 16 mg arm. Phase 2 in the US is a bridge. It is not an FDA sticker.

Retatrutide’s type 2 diabetes talk sits in the 2023 Lancet Phase 2 and later follow-on work. Same rule. Diabetes endpoints and obesity endpoints are related talks. They are not the same shopping list.

Access lanes: China label vs US trial vs research catalog

Three lanes. Keep them.

Labeled / approved drugs have an application, a label, a use, and manufacturing the agency inspects. Semaglutide and tirzepatide live there in the US for obesity and diabetes uses today. Innovent announced that China’s NMPA approved mazdutide for chronic weight management in June 2025. That is a China label conversation. It is not an FDA retail pen you fill at a US pharmacy. Retatrutide does not inherit a US sticker because the receptor count went up.

Compounding is a pharmacy lane. A 503A pharmacy compounds for a patient with a prescription. That lane has its own FDA fights, shortage rules, and state-board oversight. A compounded script is still not a branded Phase 3 program.

Research catalogs sell named chemicals for research use. COA if you are lucky. “Not for human consumption” on the page. Forums treat that line as a wink. I do not. A research-use vial labeled mazdutide, reta, GLP-3, or triple regulator is a catalog SKU. It is not GLORY-1. It is not the Lilly trial product. It is not Wegovy. It is not Zepbound.

I am not going to tell you to buy a research chemical for human use. I am not going to tell you to skip a doctor. I am going to tell you to name the lane before you name the SKU.

Lee’s Drive sheets do not carry a public mazdutide product URL. So this page does not invent a mazdutide partner box. Retatrutide-class research presentations, when they are actually live, live on the retatrutide map. This URL is the comparison. That URL is the triple-agonist catalog conversation. Keep the jobs separate.

Myths that waste your time

• “Triple always beats dual.” Not proven head-to-head. Extra receptor is extra biology, not extra permission.
• “Mazdutide is just retatrutide without GIP, so stack GIP.” That is fan fiction. These are engineered peptides, not Lego.
• “China approval means I can order it like creatine.” No. A China NMPA label is not a US FDA label and not a grocery tub. See creatine benefits if you wanted the actual grocery-aisle map.
• “A research vial is the trial product.” No. Different manufacturing. Different claims you are allowed to make. Different thing in your hand.
• “Liver curiosity means I can skip imaging.” No. The glucagon receptor sits on liver cells. That is why the papers exist. It is not a home liver protocol.

How a beginner should think about mazdutide vs retatrutide

Start with the question, not the bottle.

Are you trying to understand why one molecule hits two receptors and the other hits three? Stay here.

Are you trying to decide whether a prescription incretin belongs in your medical plan? That is a clinician visit. Not a reconstitution calculator. Not a coupon code.

Are you trying to copy a compounding protocol from a forum because the name sounded like the pen? You are copying a shopping cart.

Here is the order I give beginners.

1. Read first. The Start Here page exists so you do not run a dual or a triple on day one because a podcast guest stacked it on a whiteboard.

2. Name the receptors. Semaglutide: GLP-1. Tirzepatide: GIP + GLP-1. Mazdutide: GLP-1 + glucagon, no GIP. Retatrutide: GIP + GLP-1 + glucagon. If you cannot say that in one breath, close the tab.

3. Separate the lanes. China label. US trial. Compounded script. Research catalog. Do not mash them because both words have “peptide” in a caption.

4. Match the job. If the job is learning mazdutide vs retatrutide, you do not need a vial. If the job is the wider research-fragment map, go to peptides for weight loss. If the job is the triple-agonist file itself, go to retatrutide.

5. Ask before you buy random. The free Knowledge Base is where sourcing questions belong. Pro is where the protocol library lives. Public pages like this one exist so Google stops lying to you.

If a freeze-dried cake is even on the table, learn the math before you invent a protocol. How to reconstitute peptides covers bacteriostatic water, U-100 syringe ticks, and not wasting product on foam. That article is technique. It is not a mazdutide protocol. It is not a retatrutide protocol. I will not dump milligrams-and-days on a public URL. That is Pro on purpose.

Who this page is for

This page is for you if you typed mazdutide vs retatrutide, IBI362, LY3305677, LY3437943, dual glucagon, triple agonist, or “the one with the liver receptor” and want the map before you spend money.

This page is not for you if you want a diagnosis for obesity, type 2 diabetes, fatty liver, or “broken metabolism” from a blog. Those are clinician talks. A trial-stage molecule and a research bottle do not replace that visit.

Frequently asked questions about mazdutide vs retatrutide

Is mazdutide the same as retatrutide?

No. Mazdutide is GLP-1 plus glucagon. Retatrutide adds GIP. Different molecule. Different development program. Different papers.

Is mazdutide FDA-approved for weight loss in the US?

Not as a general retail obesity sticker this page is claiming. Innovent announced China NMPA approval for chronic weight management in June 2025. A US Phase 2 exists. Ask for the FDA label before you believe a caption about a US pen.

Is retatrutide FDA-approved?

Not as a general retail obesity sticker this page is claiming. The public teaching file is Phase 2 plus later papers. Still-in-trials status is not a Wegovy or Zepbound label. Details live on retatrutide.

Can I compare the weight-loss percentages and pick a winner?

You can compare them as a reader. You cannot treat that collage as a head-to-head. Different populations. Different doses. Different lengths. No shared trial I can cite.

Does the glucagon receptor mean these drugs treat fatty liver?

It means liver-fat talks show up in the research file. Retatrutide has a small imaging substudy with a large relative liver-fat move. That is not a US liver-disease label. Mazdutide’s glucagon bet includes hepatic energy-use talks. Scans belong with a clinician. This page will not write a liver protocol.

Is a research-catalog “mazd” or “reta” the trial product?

No. A research-use chemical sold for lab research is not the Innovent or Lilly trial product. It is not an approved branded pen. Name the lane.

Where do fragments like AOD-9604 sit?

Different job. Different map. Start on peptides for weight loss if that is the lane you meant.

Sources & Further Reading

Verified starting points. Classic discovery plus Phase 2 and Phase 3 primaries. Not a protocol. Not a drug label. Not an endorsement to self-treat.

• GLORY-1 Phase 3 obesity, NEJM 2025 — PubMed 40421736
• GLORY-2 Phase 3 9 mg obesity, JAMA 2026 — PubMed 42251595
• US Phase 2 mazdutide obesity, Lancet Diabetes Endocrinol 2026 — PubMed 42628555
• DREAMS-1 mazdutide vs placebo in T2D, Nature 2026 — PubMed 41407859
• DREAMS-2 mazdutide vs dulaglutide in T2D, Nature 2026 — PubMed 41407860
• LY3437943 triple agonist discovery-to-clinic, Cell Metab 2022 — PubMed 35985340
• Retatrutide Phase 2 obesity, NEJM 2023 — PubMed 37366315
• Retatrutide Phase 2 type 2 diabetes, Lancet 2023 — PubMed 37385280
• Retatrutide MASLD liver-fat substudy, Nat Med 2024 — PubMed 38858523
• Retatrutide T2D inadequate-control paper, Lancet 2026 — PubMed 42250575
• SURMOUNT-5 tirzepatide vs semaglutide, NEJM 2025 — PubMed 40353578

Read primary sources. Do not treat a PubMed ID as a shopping list.

The bottom line

Mazdutide vs retatrutide is dual versus triple. GLP-1 plus glucagon versus GIP plus GLP-1 plus glucagon. Same glucagon receptor. Not the same drug. Real papers. Real Phase 3 on the mazdutide China obesity file. Real Phase 2 on the retatrutide global file. No honest head-to-head. No US FDA retail twin of Zepbound for either molecule on this page.

Keep the lanes. Read the papers. Do not buy a research cake because a caption told you it was the next FDA pen. Do not skip a clinician because a dual agonist has a liver-sounding receptor.

If you need the beginner on-ramp, use Start Here and what are peptides. Reconstitution math lives on how to reconstitute peptides. Adjacent reading: retatrutide, tirzepatide vs semaglutide, peptides for weight loss, creatine benefits, and the Peptide Playbook.

I built Peptides & Pump so you can get this without a guru tax. If you want the protocol library, member discussions, and a place to think out loud before you spend money, that is Pro. If you are not ready to pay, use the free Knowledge Base first. Then come back and argue with me when you have read more than a caption.

---

Supplier footnote: This comparison page does not hero a mazdutide research SKU. Lee’s Drive sheets do not carry a public mazdutide product URL, so I will not invent a box. Retatrutide-class research presentations, when they are live, sit on the retatrutide map. Browse wider catalogs via BioLongevity home (code LEE15), Limitless home (code LEE20), Paramount home (code LEE10), Peptira home (code LEE), and S1 shop (code LEE10). Match the product to the job. Do not collect bottles. A research catalog is not a labeled obesity drug.

Disclaimer. This article is for educational and research purposes only. It is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Mazdutide, IBI362, LY3305677, retatrutide, LY3437943, dual agonists, triple agonists, and related research-catalog presentations are not presented here as treatments for obesity, type 2 diabetes, fatty liver, MASLD, aging, metabolic syndrome, or any other condition. A medicine approved in one country is not automatically an FDA-approved retail drug in another. A research-catalog product is not a compounded prescription and is not a labeled obesity or diabetes drug. Always consult a qualified healthcare provider before starting any peptide, drug, supplement, or protocol, especially if you have a medical condition or take prescription medication. Peptides & Pump does not sell peptides.

Affiliate disclosure. Some links on this page are affiliate links. If you buy through them, I may earn a commission at no extra cost to you. Codes LEE15, LEE20, LEE, and LEE10 are the ones I actually use where a coupon fires. That commission is how I keep publishing free education. I only link suppliers I am willing to put my name on.